In this study, investigators from the United States assessed their experience with percutaneous ultrasonographic (US)-guided biopsy of pancreas transplants.
The team retrospectively reviewed data from 232 percutaneous US-guided pancreas transplant biopsies performed in 88 patients.
The investigators found that of the 232 biopsies performed, 78 were for clinically indicated reasons, while 154 were for surveillance purposes.
|72% were performed while patients were receiving therapeutic aspirin.|
They found that the number of biopsy procedures per patient ranged from 1 to 9.
There were 2 needle passes performed in 85% of the biopsy procedures, and 98% were performed by using an 18-gauge biopsy device.
The team found that adequate pancreatic tissue was obtained in 96% of the procedures.
In addition, 72% were performed while patients were receiving therapeutic aspirin.
A total of 6 biopsies resulted in clinically important complications, including 3 cases of intra-abdominal hemorrhage.
Dr Thomas Atwell and colleagues concluded, “US-guided biopsy of pancreas transplants yielded tissue that was adequate more than 96% of the time“.
“Important complications in this study were few (3%) and did not appear to be related to aspirin use“.